by Eosinophilic Esophagitis or EoE is a chronic allergic inflammatory condition of the esophagus that causes esophageal dysfunction and impairment of the ability to swallow. Symptoms include dysphagia, food impaction, heartburn and acid reflux. The chronic immune cell response caused by exposure to certain allergens damages the esophagus over time requiring medical treatment.
The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 million in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
The immune cell response and allergen exposure propelling the Eosinophilic Esophagitis market is due to the chronic activation of eosinophils, a type of white blood cell, in the esophagus in response to food or environmental allergens. When a person is exposed to an allergen they are sensitive to, it can cause an inflammatory reaction in the esophagus leading to damage over time. Managing the allergic triggers through dietary or medication treatment is necessary to prevent eosinophil accumulation and reduce symptoms. Understanding the role of allergens causative of the immune response is crucial to effectively treat cases of Eosinophilic Esophagitis.
SWOT Analysis
Strength: The unique targeted therapy options and heightened awareness about the condition present an opportunity to improve care. R&D activities for developing safe and effective treatment options also provide strength.
Weakness: Limited treatment options, lack of approved drugs and diagnostic challenges remain major weaknesses. High costs involved in R&D activities can delay development of novel therapies.
Opportunity: Growing research activity and support from patient advocacy groups can help better understand the condition. This provides opportunities for companies to develop specific drugs and expand treatment algorithms.
Threats: Delay in approvals, failure of pipeline candidates and emergence of alternative treatment regimens can pose serious threats. Issues related to market access and insurance coverage can also restrict growth potentials.
Key Takeaways
The global Eosinophilic Esophagitis market is expected to witness high growth over the forecast period driven by rising disease prevalence, strong product pipelines and improved awareness. Eosinophilic Esophagitis Market Growth is estimated to be valued at US$ 245.92 million in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030.
The USA commands the largest share currently due to concentrated efforts towards condition management and research support. Europe is also emerging as a major region with substantial focus on advanced therapies.
Key players operating in the market include Thermo Fisher Scientific, Quidel, Takeda Pharmaceutical, Straumann, Siemens Healthineers, Roche Diagnostics, Pfizer Inc., and Omega Diagnostics Group PLC. These companies are focused on developing novel targeted biologics and strengthening diagnostic algorithms. Partnerships for clinical research have also increased to help address the unmet needs in Eosinophilic Esophagitis treatment.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile i
